Innovations and Product Updates Unveiled at Deltek ProjectCon 2024
HERNDON, Va., Nov. 13, 2024 /PRNewswire/ -- Deltek, the leading global provider of…
BioAdaptives, Inc. Announces Complete Product Overhaul with New Line of Scientifically Advanced Solutions
LAS VEGAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc.…
FDA Reauthorizes Swedish Matchs General snus as a Modified Risk Tobacco Product
Philip Morris International affiliate, Swedish Match, earned first-ever FDA authorization for a…
TAILG Unveils New Product S96MAX at EICMA, with High-Efficiency Integrated Motor and Fast Charging Technology
MILAN, Nov. 6, 2024 /PRNewswire/ -- As the world's leading electric two-wheeler…
CarbonChain has received third-party validation for its latest Corporate Carbon Footprint Accounting and Reporting Methodology and Product Carbon Footprint Accounting and Reporting Methodology
- and additional sector-specific methodologies for oil & gas, transport, and metals…
CarbonChain has received third-party validation for its latest Corporate Carbon Footprint Accounting and Reporting Methodology and Product Carbon Footprint Accounting and Reporting Methodology
- and additional sector-specific methodologies for oil & gas, transport, and metals…
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on…
TAILG Unveils New Product S96MAX at EICMA, with High-Efficiency Integrated Motor and Fast Charging Technology
MILAN, Nov. 6, 2024 /PRNewswire/ -- As the world's leading electric two-wheeler…
Approx. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for Trachoma
TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT)…
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on…